The Handoff: Your Week in Rheumatology News – 4/7/17

  • Fewer than 1 in 4 women receive osteoporosis care, including diagnosis and treatment, within 12 months after their first hip fracture, despite being recommended by national guidelines. The results of the study from the AARP Public Policy Institute were published recently in the Journal of Bone and Mineral Research.
  • ArthritisPower, a patient-led and patient-centered research registry for joint, bone, and inflammatory skin conditions, has released its first mobile app; the free mobile app is available for both iPhone and Android devices. The app allows registered patients to track their symptoms and treatments while also participating in arthritis-related research.
  • The International Osteoporosis Foundation (IOF) has awarded its 2017 President’s Award to 7 osteoporosis experts and advocates in recognition of their contributions to the IOF and promoting education and awareness of the disease in their region. The recipients were honored during a ceremony at the recent World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, March 23-26, in Florence, Italy.
  • The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris, a rare and life-threatening autoimmune disorder causing progressive painful blistering of the skin and mucous membranes. The designation was supported by data from the randomized PEMPHIX trial, the results of which were recently reported in The Lancet
  • The video below examines the case of Zoe Nguyen, a 9-year-old patient with Sjögren’s syndrome, through the eyes of her mother, Thu Nguyen, and members of the treatment team at the Hospital for Special Surgery in New York City.  Dr. Nancy Pan, pediatric rheumatologist at the HSS, discusses the challenges in treating pediatric patients and communicating the complexities of auto-immune disease.

Related Articles

follow @RheumAdvisor